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Abstract
 
We investigated whether cysteinyl leukotrienes (cysLT) are intracrine signal transducers that
regulate human eosinophil degranulation mechanisms. Interleukin (IL)-16, eotaxin, and
RANTES stimulate vesicular transport–mediated release of preformed, granule-derived IL-4
and RANTES from eosinophils and the synthesis at intracellular lipid bodies of LTC
 
4
 
, the dom-
inant 5-lipoxygenase–derived eicosanoid in eosinophils. 5-Lipoxygenase inhibitors blocked
IL-16–, eotaxin-, and RANTES-induced IL-4 release; but neither exogenous LTC
 
4
 
, LTD
 
4
 
,
nor LTE
 
4
 
 elicited IL-4 release. Only after membrane permeabilization enabled cysLTs to enter
eosinophils did LTC
 
4
 
 and LTD
 
4
 
 stimulate IL-4, but not RANTES, release. LTC
 
4
 
-elicited IL-4
release was pertussis toxin inhibitable, but inhibitors of the two known G protein–coupled
cysLT receptors (cysLTRs) (CysLT1 and CysLT2) did not block LTC
 
4
 
-elicited IL-4 release.
LTC
 
4
 
 was 10-fold more potent than LTD
 
4
 
 and at low concentrations (0.3–3 nM) elicited, and
at higher concentrations (
 
 
 
3 nM) inhibited, IL-4 release from permeabilized eosinophils. Like-
wise with intact eosinophils, LTC
 
4
 
 export inhibitors, which increased intracellular LTC
 
4
 
, inhib-
ited eotaxin-elicited IL-4 release. Thus, LTC
 
4
 
 acts, via an intracellular cysLTR distinct from
CysLT1 or CysLT2, as a signal transducer to selectively regulate IL-4 release. These results
demonstrate that LTC
 
4
 
, well recognized as a paracrine mediator, may also dynamically govern
inflammatory and immune responses as an intracrine mediator of eosinophil cytokine secretion.
Key words: eotaxin • interleukin-16 • RANTES • leukotriene C
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Introduction
 
Eosinophils, one of the principal cell types recruited to and
activated at sites of allergic inflammation, are major partici-
pants in the pathogenesis of asthma and other forms of aller-
gic disorders (1, 2). Eosinophils have the potential to gen-
erate and release diverse lipid and protein mediators critical
to the development and perpetuation of allergic inflamma-
tion. Eosinophils are major sources of cysteinyl leuko-
trienes (cysLTs),
 
*
 
 LTC
 
4
 
 and its extracellular derivatives,
LTD
 
4
 
 and LTE
 
4
 
 (3). These 5-lipoxygenase (LO) pathway–
derived eicosanoids have many well recognized actions as
paracrine mediators, causing bronchoconstriction, mucous
hypersecretion, increased microvascular permeability,
bronchial hyperresponsiveness, and eosinophil infiltration
(4–6). In addition, eosinophil-specific granules contain
proteins that include not only their distinctive cationic
granule proteins, but also over two dozen preformed cy-
tokines (7). Amongst these eosinophil-derived cytokines
are the CC chemokines, RANTES (8) and eotaxin (9), and
the prototypical Th2 cytokine, IL-4 (10, 11). Like eosino-
phils, IL-4 is a hallmark of allergic and parasitic disorders.
IL-4 contributes to the polarization toward Th2 differenti-
ation and promotes IgE class switching (12). The actions of
IL-4 are not limited to the initiation of Th2 responses, but
may also stimulate other cellular responses that contribute
to manifestations of allergic diseases (12, 13). Unlike CD4
 
 
 
T cells, eosinophils store IL-4 (11), RANTES (14, 15), and
eotaxin (9), already preformed within eosinophil specific
granules. Preformed IL-4 and RANTES may be rapidly re-
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leased within minutes from eosinophil granules by vesicular
transport (14–16), but the physiological stimuli and intra-
cellular signal transduction mechanisms that elicit their re-
lease are not yet fully defined.
For the generation of cysLTs in eosinophils, arachidonic
acid liberated from membrane phospholipids is acted on
by 5-LO in concert with the 5-LO–activating protein
(FLAP) to form LTA
 
4
 
 (17). LTC
 
4
 
 synthase conjugates re-
duced glutathione to LTA
 
4
 
 to form LTC
 
4
 
 (18). Produc-
tion of LTC
 
4
 
 within eosinophils may occur at perinuclear
membranes or cytoplasmic lipid bodies (17, 19, 20). LTC
 
4
 
is not permeable across the plasma membrane and its re-
lease from eosinophils is mediated by a distinct ATP-
dependent export mechanism (21). Extracellularly, LTC
 
4
 
is further metabolized to LTD
 
4
 
 by 
 
 
 
-glutamyl transpepti-
dase or 
 
 
 
-glutamyl leukotrienase (22, 23) and to LTE
 
4
 
 by a
dipeptidase (24). These cysLTs exert their actions by
engaging specific receptors. To date, two cysLT recep-
tors (cysLTRs) have been cloned and characterized, the
CysLT1 and CysLT2 receptors (25–28). These receptors
can be distinguished with pharmacologic inhibitors and by
their differing ligand binding affinities, as studied in trans-
fected cells. CysLT1, which is also activated by the
pyriminidergic ligand, uridine diphosphate
 
 
 
(UDP) (29),
binds LTD
 
4
 
 with a 10-fold greater affinity than it binds
LTC
 
4
 
 (IC
 
50
 
’s of 
 
 
 
1 vs. 
 
 
 
350 nM, respectively) (25),
whereas CysLT2 binds LTC
 
4
 
 and LTD
 
4
 
 with equal affini-
ties (IC
 
50
 
’s of 
 
 
 
3–7 nM) (27, 28). In addition, various
findings suggest the existence of other, not yet cloned,
cysLTRs (30–32).
Understanding the mechanisms governing the synthesis
of eosinophil cysLTs and their potential actions on eosino-
phils themselves are important because it is increasingly
likely that eicosanoids synthesized within cells, including
eosinophils, may have other roles in regulating cell func-
tions, in addition to the more recognized paracrine activi-
ties in inflammation. Indeed, eicosanoids and related lipids
are increasingly being recognized to have autocrine effects.
For instance, eosinophil cysLTs exert autocrine effects to
enhance eosinophil survival (33). The enhanced plasma
membrane expression of activation-related CD69 on hu-
man eosinophils induced by platelet-activating factor (PAF)
and IL-5 is dependent on endogenous eosinophil-derived
5-LO metabolites (34).
Although eosinophils express the two known, seven
transmembrane spanning, G protein–coupled cysLTRs,
CysLT1 and CysLT2 (28, 35), little is known about the
plasma membrane or intracellular distribution of these or
other eicosanoid receptors in eosinophils. On other cells,
expression of specific G protein–coupled prostaglandin re-
ceptors is beginning to be localized at intracellular sites, in-
cluding the nuclear envelope (36). The localization of
cyclooxygenase and LO pathway enzymes and their intra-
cellular eicosanoid-specific receptors at the nuclear enve-
lope and the nucleoplasm may relate less to paracrine medi-
ator formation and more to intracrine signal-transducing
activities pertinent to more local transcriptional or other
cellular functions (37, 38).
 
We have evaluated whether eosinophil-derived cysLTs
function as autocrine or even intracrine mediators involved
in the stimulated release of IL-4 from eosinophils. We find
that CCR3 chemokine receptor–initiated signaling, which
elicits the vesicular transport–mediated release of pre-
formed IL-4 from eosinophils (16, 39), is dependent on the
formation of new 5-LO pathway–derived eicosanoids. En-
dogenous LTC
 
4
 
 formed at eosinophil lipid bodies, and not
extracellular LTC
 
4
 
, acting via distinct intracellular cys-
LTRs, is an intracrine downstream signaling mediator of
CCR3-elicited IL-4 release from eosinophils.
 
Materials and Methods
 
Eosinophil Purification.
 
Peripheral blood was obtained with in-
formed consent from 16 normal donors, and eosinophils were
isolated with minor modifications of procedures described previ-
ously (15). In brief, after citrate-anticoagulated blood was mixed
with 6% dextran saline (McGaw) to facilitate erythrocyte sedi-
mentation, the leukocyte-enriched plasma was overlaid onto Fi-
coll-Paque Plus (Amersham Biosciences) and centrifuged at 250 
 
g
 
for 20 min. Granulocyte-enriched cell pellets were collected,
washed at 4
 
 
 
C with calcium- and magnesium-free HBSS
(HBSS
 
 
 
/
 
 
 
), and depleted of erythrocytes by hypotonic saline ly-
sis. Eosinophils were negatively selected using the StemSep™ sys-
tem (StemCell Technologies Inc.) with an eosinophil enrichment
mixture of antibodies against CD16, CD2, CD14, CD19 and
CD56 plus magnetic colloid. The viability of freshly isolated cells
was 
 
 
 
95% (by trypan blue exclusion) and eosinophil purity was
 
 
 
99% (by HEMA3
 
®
 
 staining; Fisher Scientific). Purified cell
suspensions were adjusted to 10
 
6
 
 or 15 
 
 
 
 10
 
6
 
 cells/ml in RPMI
1640 medium containing 0.1% endotoxin-free ovalbumin
(Sigma-Aldrich) for use in fluid- or gel-phase assays, respectively.
 
LTC
 
4
 
 Assays.
 
Eosinophil suspensions (10
 
6
 
 cells/ml) were
washed in HBSS
 
 
 
/
 
 
 
, resuspended in 1 ml of HBSS containing
calcium and magnesium, and stimulated with 0.1 
 
 
 
M A23187
(Sigma-Aldrich) for 15 min (37
 
 
 
C). Reactions were stopped on
ice, and cell suspensions were centrifuged (500 
 
g
 
 for 10 min;
4
 
 
 
C). Cell pellets were extracted for 30 min with methanol and
centrifuged. Methanol extracts were dried under nitrogen and re-
suspended in HBSS
 
 
 
/
 
 
 
 to volumes equivalent to 10
 
6
 
 eosinophils/
ml. Cell supernatants and pellet extracts were assayed for LTC
 
4
 
 by
enzyme immunoassay (sensitivity 
 
 
 
7.8 pg/ml) (Cayman Chemi-
cal) for detection of released and intracellular levels of LTC
 
4
 
, re-
spectively. Intracellular formation of LTC
 
4
 
 within eosinophils
embedded in an agarose matrix was evaluated as described previ-
ously using carbodiimide fixation of newly formed LTC
 
4
 
 before
its immunofluorescent localization with an Alexa-488–labeled
(Molecular Probes) rat anti-LTC
 
4
 
/LTD
 
4
 
/LTE
 
4
 
 mAb (clone 6E7;
Sigma-Aldrich) (20).
 
EliCell Assays for Detecting IL-4 and RANTES Secretion.
 
 The
EliCell assay, a gel-phase dual antibody capture and detection assay
based on microscopic observations of individual viable cells, was
performed as detailed (15, 16) to enumerate the proportions of
eosinophils secreting preformed IL-4 or RANTES and to elec-
tronically quantitate (in arbitrary units 
 
 
 
10
 
6
 
) the average relative
amounts of each cytokine secreted. Biotinylated goat polyclonal
antibodies against IL-4 and RANTES (each at 20 
 
 
 
g/ml; R&D
Systems) were used as capturing antibodies and paired with
Alexa546-labeled anti–IL-4 and anti-RANTES mAb (400 
 
 
 
l of 10
 
 
 
g/ml; R&D Systems) to detect released IL-4 and RANTES, re-
spectively. Alexa546 labeling was performed as per a protocol from 
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Molecular Probes. Controls to ascertain the specificity of extracel-
lular immunodetection of these two cytokines and to confirm that
the detected cytokines were not from the intracellular pool were
performed. No IL-4 or RANTES staining was found either when
Alexa546-labeled mouse IgG
 
1
 
 was used as a nonimmune isotype
control or when the biotinylated capture antibodies (necessary to
immobilize cytokines at their extracellular sites of release) was sub-
stituted with a biotinylated irrelevant control antibody.
 
Stimuli and Treatments.
 
 Eosinophils were stimulated with IL-
16 (100 nM; R&D Systems), RANTES (6 nM; R&D Systems),
eotaxin (6 nM; R&D Systems), the cysLTs, LTC
 
4
 
, LTD
 
4
 
, or
LTE
 
4
 
, (0.03–3,000 nM; Cayman Chemical), PAF (1 
 
 
 
M), 5(S)-
hydroxyeicosatetranoic acid (HETE) (1, 10, and 100 nM; Cay-
man Chemical), uridine triphosphate (UTP) or UDP (each 3 and
3,000 nM; Sigma-Aldrich), or calcium ionophore (0.5 
 
 
 
M;
Sigma-Aldrich) for time periods ranging from 5 min to 3 h.
For inhibition studies, cells were pretreated for 30 min with
20 ng/ml pertussis toxin (PTX; Calbiochem); 5-LO pathway
inhibitors, MK886 (a FLAP and LTC
 
4
 
 synthase inhibitor) or
AA861 (5-LO inhibitor) (10 
 
 
 
M; Biomol); brefeldin A (BFA)
(0.1 and 1 
 
 
 
g/ml; Biomol); the protein kinase C (PKC) inhibi-
tors, chelerythrine (10 
 
 
 
M) and staurosporin and calphostin C
(1 
 
 
 
M; Biomol); the phosphoinositide-3 kinase (PI3K) inhibi-
tors, wortmannin (1 
 
 
 
M) and LY294002 (10 
 
 
 
M; Biomol); the
tyrosine kinase inhibitors, 10 
 
 
 
M herbimycin and 10 
 
 
 
M
genistein (Biomol); the mitogen-activated protein (MAP) kinase
inhibitors, 10 
 
 
 
M PD98059, 10 
 
 
 
M U0126, 10 
 
 
 
M and
SB203580 (Biomol); or their vehicles, as indicated. Alter-
natively, cells were coincubated with cysLTR antagonists,
MK571, LY171833, or BAYu9773 (10 
 
 
 
M; Biomol); eotaxin
(6 nM); inhibitors of LTC
 
4
 
 carrier-proteins, probenecid (0.5–2
mM; Sigma-Aldrich); MK571 (10 
 
 
 
M) and cyclosporin A (1
 
 
 
g/ml; Sigma-Aldrich); or their vehicles, as indicated. Stock so-
lutions of stimuli and inhibitors were prepared in HBSS
 
 
 
/
 
 
 
containing 0.1% of endotoxin-free ovalbumin, aliquoted
and stored at 
 
 
 
20
 
 
 
C. AA861, MK886, LY294002, calphostin
C, herbimycin, genistein, PD98059, U0126, SB203580,
LY171833, BAYu9773, and A23187 were diluted in DMSO.
The final DMSO concentration was 
 
 
 
0.01% and had no effect
on eosinophils.
 
Permeabilization of Viable Eosinophils.
 
To enable the entrance
of cysLTs into eosinophils, freshly purified eosinophils (at 2 
 
 
 
10
 
6
 
 cells/ml) were semi-permeabilized using a protocol pub-
lished elsewhere (40) with minor modifications. In brief, cells
were incubated for 1 h at room temperature in a semi-permeant
solution (1% methanol and 1% DMSO in HBSS
 
 
 
/
 
 
 
). Cells were
washed in RPMI, mixed with agarose matrix, and used in Eli-
Cell assay. Alternatively, after 1 h of semi-permeabilization, eo-
sinophils were washed and either stained with osmium for analy-
sis of lipid body content (41) or checked by flow cytometry, as
described earlier (16), to verify that the normal content of pre-
formed IL-4 was unchanged. The success of the permeabilization
procedure was confirmed by the ability of eosinophils to rapidly
incorporate 10 
 
 
 
M pyrenedodecanoic acid (p96; Molecular
Probes), a blue fluorescent fatty acid, in their lipid bodies within
15 min, whereas control nonpermeabilized cells showed no p96
staining (not depicted).
 
Statistical Analysis.
 
Data were expressed as means 
 
 
 
 SD. Per-
cent inhibition with antagonists was calculated in comparison to
stimulated increases in LTC
 
4
 
 production or IL-4 release above
baselines. Statistical comparisons were done by ANOVA fol-
lowed by Newman-Keuls Student’s test. Differences were con-
sidered significant when P   0.05.
Results
Endogenous 5-LO Pathway-derived Eicosanoids Regulate
Eosinophil IL-4 Secretion. We have shown previously that
preformed eosinophil granule stores of IL-4 may be rapidly
and selectively released extracellularly by vesicular trans-
port–mediated mechanisms activated via CCR3 either by
exogenous eotaxin and RANTES or by these chemokines
released from IL-16–stimulated eosinophils (16, 39). These
CCR3-acting chemokines also prime calcium ionophore
(A23187)–activated eosinophils for greater extracellular re-
lease of the dominant 5-LO eicosanoid of eosinophils,
LTC4, and directly elicit 5-LO activation and low level
formation of LTC4 detectable intracellularly at lipid body
domains (20). Therefore, we investigated whether 5-LO–
derived eicosanoids might have signal-transducing roles in
regulating cytokine secretion from human eosinophils. Pre-
treatment with two mechanistically distinct inhibitors of
5-LO (AA861 and MK886) blocked IL-16–, eotaxin-, and
RANTES-induced IL-4 release from eosinophils (Fig. 1
A). In contrast, pretreatment of eosinophils with either
AA861 or MK886 did not inhibit IL-16– or eotaxin-
induced release of RANTES (Fig. 1 B). The 5-LO inhibi-
tors did not inhibit the cytolytic and exocytotic release of
either IL-4 or RANTES elicited by A23187 (Fig. 1). Thus,
eosinophil-derived 5-LO metabolites participate in CCR3
Figure 1. Effects of 5-LO pathway inhibitors on IL-16–induced, eo-
taxin-, RANTES-, and calcium ionophore (A23187)–induced IL-4 (A)
or RANTES (B) release. Human eosinophils were pretreated for 30 min
with 10  M AA861 or MK886, as indicated. Cells were mixed in EliCell
gel-matrix and stimulated for 1 h with IL-16 (100 nM), eotaxin (6 nM),
RANTES (6 nM), or A23187 (0.5  M). Results were expressed as the
percentages of eosinophils releasing IL-4 or RANTES extracellularly.
Values are means   SD from three independent assays.   and * represent
P   0.01 compared with nonstimulated and cytokine/chemokine-stimu-
lated eosinophils, respectively. Nonstimulated eosinophils exhibited 8  
4% positivity for IL-4 (n   7) and 5   3% positivity for RANTES release
(n   5).844 Endogenous LTC4-mediated Eosinophil IL-4 Secretion
chemokine-initiated signaling to release IL-4, but not
RANTES, from eosinophils.
Cysteinyl LTs Are Intracrine Signals Regulating Eosinophil
IL-4 Secretion. We evaluated which 5-LO pathway–
derived eicosanoids, generated within and potentially re-
leased from eosinophils in response to CCR3 activation,
were involved in IL-4 secretion from eosinophils. We first
investigated LTC4 and its extracellular derivatives, LTD4
and LTE4. As shown in Fig. 2 A (open symbols), none of
the three cysLTs at concentrations ranging from 0.03 to
3,000 nM were able to induce IL-4 or RANTES (not de-
picted) release from intact eosinophils. Likewise, exoge-
nous 5-HETE (1, 10, and 100 nM), another potential eo-
sinophil 5-LO–derived eicosanoid, failed to trigger IL-4
release from intact eosinophils (not depicted). 1  M PAF,
which can activate the 5-LO pathway in eosinophils (41,
42), also did not elicit IL-4 release (not depicted).
To ascertain whether the 5-LO product LTC4 was nec-
essary but not sufficient to induce IL-4 secretion from eo-
sinophils, eosinophils were pretreated with 5-LO pathway
inhibitors (AA861 or MK886) and stimulated with IL-16
with or without exogenous LTC4 (3 or 3,000 nM). As
shown in Fig. 2 B, the co-stimulation of eosinophils with
exogenous LTC4 was unable to restore the ability of IL-16
to induce IL-4 release that was blocked by the 5-LO inhib-
itors. These data indicate that extracellular stimulation with
exogenous LTC4 is ineffective in regulating IL-4 release
from intact eosinophils.
Because cysLTs are not permeable across the plasma
membrane and we have shown previously that LTC4 is
synthesized intracellularly at cytoplasmic lipid bodies
within IL-16–, eotaxin-, or RANTES-stimulated eosino-
phils (20, 39), we investigated whether cysLTs acting intra-
cellularly could trigger IL-4 release. To investigate such
potential intracrine signaling, we permeabilized eosinophils
in order to allow impermeable cysLTs to enter eosinophils.
We established that permeabilized eosinophils in compari-
son with intact (nonpermeabilized) eosinophils retained
their basal content of IL-4 (as assessed by flow cytometry)
and their normal resting numbers of cytoplasmic lipid bod-
ies, and were normally responsive to eotaxin in forming
new lipid bodies (not depicted) or releasing IL-4 (Fig. 3).
In contrast to intact eosinophils, both LTC4 and LTD4
stimulated IL-4 release (Fig. 2 A, closed symbols) but not
RANTES release (not depicted) from permeabilized eo-
sinophils. LTC4 was more active than LTD4, with LTC4
stimulating greater percentages of eosinophils to release IL-4
extracellularly and with peak activity (0.3 nM) at a 10-fold
lower concentration than with LTD4. Notably, higher
concentrations ( 30 nM) of either LTC4 or LTD4 did not
elicit IL-4 release (Fig. 2 A). Neither LTE4 (Fig. 2 B, closed
symbols), 5-HETE (not depicted), nor PAF (not depicted)
stimulated IL-4 release from permeabilized eosinophils.
Therefore, intracellular LTC4 formed after 5-LO activation
Figure 2. Exogenous LTC4 and LTD4, but not LTE4, stimulate IL-4
secretion only from plasma membrane–permeabilized eosinophils. (A) In-
tact (open symbols) or permeabilized (closed symbols) viable eosinophils
were stimulated for 3 h with a range of cysLT concentrations (0.03–3,000
nM), as indicated. Results were expressed as the percentages of eosino-
phils releasing IL-4 extracellularly. Values are representative from three
independent assays. (B) Exogenous LTC4 was not able to restore IL-16–
induced IL-4 release from intact eosinophils blocked by pretreatments (30
min) with 5-LO pathway inhibitors (AA861 and MK886 at 10  M). Val-
ues are means   SD from three independent assays.   and * represent
P   0.01 compared with nonstimulated (7   2% positive, dashed line)
and IL-16–stimulated eosinophils, respectively.
Figure 3. High concentrations of intracellular LTC4 block eotaxin-
induced IL-4 secretion from plasma membrane–permeabilized eosinophils.
Intact (open bars) and permeabilized (closed bars) eosinophils were co-
stimulated with 6 nM eotaxin plus different concentrations (0.03–3,000
nM) of LTC4 (as indicated) for 3 h. Results were expressed as the percent-
ages of eosinophils exhibiting secreted extracellular IL-4. Values are means  
SD from three independent assays.   and * represent P   0.01 compared
with nonstimulated and eotaxin-stimulated eosinophils, respectively.845 Bandeira-Melo et al.
functions even at low concentrations as an intracrine, and
not extracellular autocrine, mediator to regulate the differ-
ential secretion of IL-4 (vs. RANTES) induced by IL-16,
eotaxin, or RANTES.
Activation of a Novel Intracellular CysLTR Elicits IL-4 Se-
cretion. The characteristics of the receptor-mediated sig-
naling initiated by intracrine LTC4 were evaluated. Pre-
treatment of eosinophils with pertussis toxin (Fig. 4 A)
significantly inhibited LTC4- and LTD4-elicited IL-4 se-
cretion from permeabilized eosinophils, suggesting the in-
volvement of a Gi /o-like protein-coupled cysLTR. The
two G protein–coupled cysLTRs that have been cloned
and characterized are CysLT1 and CysLT2 (25–28). Hu-
man eosinophils contain mRNA transcripts for both
CysLT1and CysLT2 (28, 35). These receptors can be dis-
tinguished, in part, by their ligand binding affinities as stud-
ied in transfected cells. CysLT1, which is also activated by
the pyriminidergic ligand, UDP (29), binds LTD4 with
a 10-fold greater affinity than it binds LTC4, whereas
CysLT2 binds LTC4 and LTD4 with equal affinities. In
contrast, the intracellular cysLTR mediating signaling for
IL-4 release from permeabilized eosinophils was activated
by LTC4 at 10-fold lower concentrations than LTD4 (Fig.
2 A; 0.3 vs. 3 nM, respectively). Moreover, the pyrimini-
dergic ligands UTP and UDP (each at 3 and 3,000 nM),
the latter an agonist for CysLT1, did not elicit IL-4 release
from permeabilized eosinophils (not depicted).
We also used specific receptor antagonists of CysLT1
(MK571 and LY171883) that do not inhibit CysLT2, and
BAYu9773, a receptor antagonist for CysLT1 that also de-
sensitizes CysLT2 to cysLTs (27). As shown in Fig. 4 A,
these antagonists of the two known cysLTRs failed to in-
hibit LTC4-elicited IL-4 secretion from permeabilized
eosinophils, providing pharmacologic evidence that the in-
tracrine signaling of LTC4 was mediated by neither of the
two known cysLTRs. In intact eosinophils stimulated to
release IL-4 with either IL-16 or eotaxin, neither the
CysLT1 antagonist LY171883 nor the dual receptor antag-
onist BAYu9773 inhibited IL-4 release (Fig. 4 B), again in-
dicating in intact eosinophils that intracrine LTC4 signaling
was not acting via either CysLT1 or CysLT2 receptors.
Interestingly, pretreatment of eosinophils with MK571
did inhibit IL-4 secretion induced by both IL-16 and eo-
taxin (Fig. 4 B). MK571, in addition to being a CysLT1
antagonist, is also an inhibitor of multidrug resistance pro-
tein 1 (MRP1; references 43, 44), a protein carrier that
mediates the extracellular export of impermeable LTC4
from within cells (45, 46). To assess whether MK571’s ef-
fect depended on its activity as an MRP1 inhibitor of
LTC4 export, we evaluated its effect on the intracellular
levels of LTC4 within IL-16–stimulated cells and compared
its effect with another known inhibitor of LTC4 export
from eosinophils, probenecid (21). With intact IL-16–stim-
ulated eosinophils, both inhibitors of LTC4 transport,
probenecid and MK571, blocked extracellular release of
LTC4 into eosinophil supernatants (see Fig. 5 C), increased
intracellular LTC4 levels (see Fig. 5 B), and inhibited IL-4
release (Fig. 5 A). Neither probenecid nor MK571 altered
the intracellular content of IL-4, as assessed by flow cytom-
etry in permeabilized eosinophils (16) (n    3, not de-
picted). In contrast, control agents, LY171883, the CysLT1
inhibitor, and cyclosporin A, an inhibitor of another ATP-
dependent, multidrug resistance P-glycoprotein transporter
not involved in LTC4 transport (47, 48), were without in-
hibitory effects on these three responses (Fig. 5). With in-
hibition of LTC4 extracellular export in these IL-16–stimu-
lated eosinophils, intracellular LTC4 levels would be well
in excess of  5 nM LTC4 concentrations measured in eo-
sinophil extracts from 106 eosinophils/ml. The inhibition
of IL-4 release by these elevated intracellular levels of LTC4
would accord with the absence of IL-4 release with perme-
abilized eosinophils exposed to  30 nM LTC4 concentra-
tions either alone (Fig. 2 A) or together with eotaxin stim-
ulation (Fig. 3).
We investigated the sites of LTC4 formation using im-
munofluorescent localization of newly formed and carbodi-
imide-immobilized LTC4 (20). As reported previously (20,
39), in IL-16– and RANTES-stimulated eosinophils (Fig. 6
A), agonist-induced and newly synthesized LTC4 was fo-
cally localized at cytoplasmic lipid bodies. With inhibition
of LTC4 export with either probenecid or MK571, both
the percentages of eosinophils and the numbers of intracel-
lular lipid bodies exhibiting immunodetectable LTC4 in-
creased (Fig. 6).
Downstream Signaling of LTC4-induced Vesicular Transport-
mediated Eosinophil IL-4 Secretion. We have shown re-
cently that LTC4 production at cytoplasmic lipid
bodies within CCR3 chemokine-stimulated eosinophils
Figure 4. Effects of PTX and cysLTR antagonists on LTC4- and
LTD4-elicited IL-4 secretion from plasma membrane–permeabilized eo-
sinophils. (A) Permeabilized eosinophils were pretreated for 30 min with
PTX (20 ng/ml), MK571 (10  M), LY171883 (10  M), or BAYu9773
(10  M), and then stimulated for 3 h with LTC4 (3 nM) or LTD4 (3 nM).
(B) Intact eosinophils were pretreated as described in A, and then stimu-
lated for 1 h with 100 nM IL-16 or 6 nM eotaxin. Results were expressed
as the percentages of eosinophils exhibiting secreted extracellular IL-4.
Values are means   SD from three independent assays.   and * represent
P   0.01 compared with nonstimulated (6   3% positive) and stimulated
eosinophils, respectively.846 Endogenous LTC4-mediated Eosinophil IL-4 Secretion
depended on activation of PI3K and MAP kinases (20). With
specific kinase inhibitors, we investigated the downstream
signaling of LTC4- and eotaxin-induced IL-4 release from
eosinophils. Both LTC4 and eotaxin-induced IL-4 release
were blocked by inhibitors of PI3K (wortmannin,
LY294002) and tyrosine kinases (genistein, herbimycin A),
but not by PKC inhibitors (staurosporin, chelerythrine,
and calphostin C; Fig. 7). In contrast, the MAP kinase in-
hibitors, PD98059 and U0126 (inhibitors of the extracellu-
lar signal-regulated kinases (ERK)1/2 activating kinase
MEK [MAP ERK kinase]), and SB203586 (a p38 MAP ki-
nase inhibitor), significantly inhibited eotaxin’s actions
(Fig. 7 B) without affecting LTC4-induced IL-4 secretion
(Fig. 7 A).
In IL-16–, eotaxin-, and RANTES-stimulated eosino-
phils, the mobilization and extracellular secretion of pre-
formed IL-4 occurs rapidly by a selective, noncytotoxic,
brefeldin A (BFA)-inhibitable, vesicular transport–medi-
ated mechanism (20, 39). Similarly, LTC4-induced IL-4 re-
lease from permeabilized eosinophils was morphologically
consistent with vesicular transport (not depicted) and was
significantly inhibited by BFA (Table I), indicating that a
vesicular transport-mediated process was also responsible
for LTC4-elicited selective secretion of IL-4.
Figure 5. Blockade of the extracellular export of
endogenously produced LTC4 inhibits eosinophil
IL-4 secretion. Intact eosinophils were pretreated
for 30 min with MK571, LY171883, probenecid,
or cyclosporin A (CsA), and then stimulated with
IL-16 (100 nM) for 3 h. (A) The percentages of
eosinophils exhibiting extracellularly secreted IL-4;
(B) the intracellular concentration of LTC4 within
106 eosinophils/ml; and (C) the extracellular con-
centration of LTC4 released by 106 eosinophils/ml.
Values are means   SD from three independent
assays.   and * represent P   0.01 compared with
nonstimulated (dashed lines) and IL-16–stimulated
eosinophils, respectively.
Figure 6. Effect of blockade of LTC4 export on IL-16– and RANTES-elicited LTC4 detection at lipid bodies within eosinophils. Intact eosinophils
were pretreated for 30 min with 2 mM probenecid or 10  M MK571, and then stimulated with medium alone, IL-16 (100 nM) or RANTES for 3 h.
(A) Phase-contrast (left) and anti-LTC4 immunofluorescent (right) microscopic images of identical fields of eosinophils within an agarose matrix are
shown. Anti-LTC4 immunofluorescent images (green) are overlaid on phase-contrast images to facilitate their intracellular LTC4 localization within
eosinophils. Inserted numbers indicate lipid bodies exhibiting positive anti-LTC4 immunofluorescent staining. (B) The mean   SD percentages of
eosinophils exhibiting green immunofluorescent labeling for intracellular immunoreactive LTC4. Results in C are the mean   SD numbers of lipid bod-
ies exhibiting immunolabeling for LTC4 within each scanned eosinophil (50 cells were scanned per slide).847 Bandeira-Melo et al.
Discussion
Amongst leukocytes, eosinophils are unique, in part, due
to their complex content of proteins stored within their cy-
toplasmic granules. Mechanisms for differentially mobilizing
these granule-stored proteins for their extracellular release
may enable eosinophils to selectively and rapidly influence
various immune, inflammatory, and other responses. In
contrast to many leukocytes in which cytokines must be
synthesized de novo before their release, eosinophils within
their specific granules contain a diversity of already pre-
formed chemokines and cytokines, including nominally
Th1 and Th2 cytokines with diverse and potentially oppos-
ing functions (for review see reference 7). It is increasingly
recognized that degranulation based on wholesale exocyto-
sis that extrudes the full granule contents extracellularly
does not provide for specificity of release of selected eo-
sinophil granule contents. Instead, as yet poorly understood
mechanisms can selectively load vesicles with specific gran-
ule proteins, and these vesicles may traffic to the cell surface
to release these proteins at the cell surface (14, 16). Because
the selective release of cytokines can provide a means for
eosinophils to rapidly influence adjacent cells in normal or
inflamed tissue sites, we investigated mechanisms involved
in the selective mobilization and vesicle-mediated secretion
of specific cytokines, including IL-4, a Th2-type cytokine
with diverse actions pertinent to allergic and parasitic dis-
eases (12, 13), and the chemokine RANTES. Our current
studies provide several new insights into the signal trans-
duction processes that contribute to the selective mobiliza-
tion and release of specific granule-derived cytokines and
chemokines from eosinophils.
Although eotaxin and RANTES each act via CCR3 to
stimulate the secretion of both IL-4 and RANTES from
eosinophils (15, 16, 39), only the release of IL-4 was de-
pendent on the activation of 5-LO to form LTC4 within
eosinophils. Two 5-LO pathway inhibitors (MK886 and
AA861) blocked eotaxin- and IL-16–stimulated IL-4 re-
lease but not RANTES release (Fig. 1); in permeabilized
eosinophils, exogenous LTC4 stimulated IL-4 (Fig. 2), but
not RANTES, release. Thus, common activation via
CCR3 can be differentially linked to downstream signaling
mechanisms that for mobilization and release of IL-4, but
not RANTES, are specifically dependent on 5-LO path-
way activation to form LTC4.
Because cysLTs are not permeable across plasma mem-
branes, it was possible to determine that LTC4, formed in
response to CCR3-mediated activation, was functioning
solely as an intracrine signal-transducing mediator. Exoge-
nous LTC4 and its derivative cysLTs did not stimulate IL-4
release from intact eosinophils, but LTC4, and to a lesser
extent LTD4, did in eosinophils whose membranes were
permeabilized to enable the intracellular entry of these cys-
LTs (Fig. 2). Thus, a novel role for endogenously formed
LTC4 within eosinophils as an intracellular signal-transduc-
ing mediator has been revealed.
Stimulation of eosinophils with CCR3-acting chemo-
kines has been shown to lead to the formation of low levels
of LTC4 detectable by immunofluorescent microscopy at
intracellular lipid bodies within eosinophils in the absence
of detectable immunoassayed concentrations of extracellu-
larly released LTC4 (20). Several findings indicate that such
low level intracellular LTC4 may be functional in regulat-
ing IL-4 release. In permeabilized eosinophils, only low
Figure 7. Effect of kinase inhibitors on LTC4- and eotaxin-induced
IL-4 secretion from eosinophils. (A) Plasma membrane–permeabilized
eosinophils were pretreated for 30 min with wortmannin (1  M),
LY294002 (10  M), PD98059 (10  M), U0126 (10  M), SB203580 (10
 M), genistein (10  M), herbimycin (10  M), staurosporin (1  M),
chelerythrine (10  M), or calphostin C (1  M), and then stimulated for
3 h with LTC4 (3 nM). (B) Intact eosinophils were pretreated as described
in A and then stimulated for 1 h with eotaxin (6 nM). Results were ex-
pressed as the percentages of eosinophils exhibiting extracellular IL-4.
Values are means   SD from three independent assays.   and * represent
P   0.01 compared with nonstimulated (A, 6   3% baseline positive; B,
5   2% positive) and stimulated eosinophils, respectively.
Table I.  Vesicular Transport Mediates Intracellular LTC4-induced 
IL-4 Secretion from Eosinophils
Condition
Percent eosinophils 
releasing IL-4
IL-4 fluorescent 
intensity/cell
Medium 3.9   5.1 4   1
LTC4 37.8   7.8a 832   196a
  BFA (0.1  g/ml) 30.3   8.8 472   186b
  BFA (1  g/ml) 19.3   7.8b  111   70b
Plasma membrane–permeabilized eosinophils were pretreated for 30
min with an inhibitor of vesicle formation, BFA, and then stimulated
with 3 nM LTC4. After 3 h, IL-4 secretion was analyzed in EliCell
assays. Results are either the percentages of eosinophils exhibiting
extracellular IL-4 or the average of electronically measured
immunofluorescent intensities of extracellular IL-4 (in arbitrary units).
Values are means   SD from three independent assays.
aP   0.01 compared with nonstimulated eosinophils.
bP   0.01 compared with LTC4-stimulated eosinophils.848 Endogenous LTC4-mediated Eosinophil IL-4 Secretion
levels of LTC4 were active in stimulating IL-4 release, with
maximal activity at 0.3 nM (Fig. 2). Greater LTC4 concen-
trations ( 3 nM) were inhibitory as indicated in permeabi-
lized eosinophils (Fig. 2) and confirmed with the suppres-
sion of IL-4 release from eotaxin-stimulated, permeabilized
eosinophils (Fig. 3). Similarly, the blockade of extracellular
LTC4 export with MK571 and probenecid raised intracel-
lular LTC4 levels in intact eosinophils and inhibited IL-16–
stimulated IL-4 release. Whether the inhibition at higher
LTC4 concentrations represents high dose inhibition at a
single type of cysLTR or engagement of another antago-
nistic receptor is unknown. Thus, LTC4 has dose-depen-
dent roles as an intracrine signal-transducing mediator. No-
tably, at low intracellular concentrations, newly synthesized
LTC4, as detectable by immunofluorescent localization at
lipid bodies in eotaxin- and RANTES-stimulated eosino-
phils (20), can signal to promote IL-4 secretion. At higher
intracellular LTC4 concentrations, LTC4 inhibits this re-
lease of preformed IL-4. Agents such as MK571, which
blocks the extracellular export of LTC4 (in addition to in-
hibiting CysLT1; references 45, 46), may exert anti-inflam-
matory effects by increasing intracellular LTC4 and thereby
inhibiting the secretion of some eosinophil cytokines.
The IL-4–releasing activity of intracellular and not exog-
enous LTC4 indicated that plasma membrane expressed
cysLTRs, that for human eosinophils may include both of
the currently known cysLTRs, CysLT1and CysLT2 (28,
35), were not involved. Instead, an intracellular cysLTR
must be involved. A number of findings indicated that this
cysLTR was distinct from either CysLT1 or CysLT2.
LTC4 was 10-fold more potent than LTD4 in eliciting IL-4
release from permeabilized eosinophils. Because LTD4 is
formed extracellularly from LTC4, this is further consistent
with an intracrine role preferentially for LTC4. In contrast,
CysLT1 is more potently activated by LTD4 than LTC4,
whereas both of these cysLTs are equipotent on CysLT2
(25, 27, 28). CysLT1 can be activated by the pyriminider-
gic ligand UDP (29), but neither UDP nor UTP stimulated
IL-4 release from permeabilized eosinophils. Moreover, the
CysLT1 inhibitor LY171883 and the CysLT1 and CysLT2
dual inhibitor BAYu9773 failed to inhibit IL-4 secretion
from intact eosinophils stimulated with IL-16 or eotaxin
and from permeabilized eosinophils stimulated with LTC4
and LTD4 (Fig. 4). Thus, the intracrine activity of LTC4 is
likely mediated via a cysLTR distinct from either CysLT1
or CysLT2.
Known cysLTRs are seven transmembrane spanning re-
ceptors that may signal at least some responses via G pro-
teins. LTC4 elicitation of eosinophil IL-4 release was inhib-
ited by PTX, suggesting the intracellular cysLTR functions
via coupling to PTX-sensitive Gi /o-like proteins. Down-
stream signaling via this cysLTR to elicit IL-4 secretion re-
quired activation of PI3K and genistein- and herbimycin-
inhibitable tyrosine kinases, but not PKC or MAP kinases
(Fig. 7). PI3K and tyrosine kinase activation were also re-
quired for eotaxin and RANTES CCR3-mediated activa-
tion of IL-4 release. Because genistein- and herbimycin-
inhibitable tyrosine kinases do not block eotaxin- and
RANTES-elicited lipid body formation for enhanced
LTC4 formation (20), the roles of these tyrosine kinases in
signal transduction leading to IL-4 release is solely down-
stream of LTC4-cysLTR–initiated signaling. In contrast,
PI3K activation is required at two points in the chemo-
kine-initiated signaling. PI3K inhibitors block CCR3-act-
ing chemokines from forming new lipid bodies and gener-
ating LTC4 (20), and as shown here also block the
downstream signaling initiated by LTC4 at its receptor (Fig.
7). The MAP kinases, ERK 1/2 and p38, act proximally in
the CCR3-chemokine–initiated signaling to form LTC4
(20), but do not act downstream of the cysLTR signaling
for IL-4 release from eosinophils.
There is limited precedence for cysLTs eliciting cyto-
kine secretion. With human placental cord blood–derived
eosinophils, we have shown that cysLTs stimulate the ve-
sicular transport-mediated release of IL-4 (49), but the
findings with those IL-3– and IL-5–stimulated cells dif-
fered in several regards from what we demonstrate with
normal blood-derived eosinophils. Cord blood–derived
eosinophils responded not to LTC4 but to LTD4, which
acted extracellularly on plasma membrane receptors that
were inhibited by two inhibitors of CysLT1 (LY171833
and MK571) and required much higher concentrations of
LTD4 (10 7–10 6 M; reference 49). Human cord blood–
derived mast cells, after exposure to IL-4, also have been
shown to respond to cysLTs with the release of cytokines
(30). Exogenous LTC4 and LTD4, which were equipotent
at 10 7 M concentrations, acted on a UDP-activatable and
MK571-inhibitable cysLTR. This differs from our findings
with human eosinophils, in which the cysLTR was intra-
cellular, activatable preferentially by LTC4 at much lower
10 10–10 9 M concentrations, and not inhibitable by
CysLT1 or CysLT2 inhibitors.
In contrast to human cord blood–derived mast cells, in
which cytokine release required de novo transcription and
translation to generate new cytokines (30), a difference
with eosinophils is that they contain preformed cytokines
that can be rapidly mobilized within minutes from granule
stores and released by a BFA-inhibitable, vesicular trans-
port–mediated mechanism (Table I), which, as we have
shown previously for IL-4, does not require new IL-4 tran-
scription or protein synthesis (16). The release of granule-
derived IL-4 at the surface of eosinophils was sensitively
detected by EliCell assays at levels beneath the sensitivity
( 15 pg/ml) of conventional ELISA assays (including with
LTC4-stimulated, permeabilized eosinophils; not depicted).
A role for eosinophil-derived IL-4 has been demonstrated
in a murine system in which the intraperitoneal instillation
of Schistosoma mansoni eggs leads to the release of IL-4 de-
rived from peritoneal exudate eosinophils (50). Fundamen-
tal issues in delineating eosinophil contributions to im-
munologic reactions are understanding the stimuli and
intracellular signaling mechanisms that may selectively re-
lease some and not other preformed cytokines and chemo-
kines from granule stores. Eotaxin and RANTES elicit IL-4,
but not IL-12, release (e.g., from eosinophils; reference
39). As demonstrated here with permeabilized eosinophils,849 Bandeira-Melo et al.
LTC4 stimulated IL-4 but not RANTES release and like-
wise did not elicit IL-12 release (not depicted). Thus, some
of the specificity in secreting selective cytokines and che-
mokines from eosinophils is based on the activation of in-
tracellular LTC4 signal-transducing pathways.
In summary, our findings support a role for a novel in-
tracellular cysteinyl LT receptor, apparently distinct from
known CysLT1 or CysLT2, that functions via coupling to
PTX-sensitive Gi /o-like proteins. By means of this cys-
LTR, LTC4 can function as an intracrine signal transducer
that activates pathways that selectively mobilize IL-4, and
not RANTES, for vesicular transport–mediated extracellu-
lar release. Therefore, the generation of LTC4 within eo-
sinophils is important not only for its varied activities as an
extracellular paracrine mediator of inflammation, but also
for its role as an intracrine signal-transducing molecule that
may regulate fundamental cellular responses, including the
selective secretion of cytokines from eosinophils.
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